Your Client Rank:
Loading...
99
Updated 22-Nov-2025
| Company | Sales | Gross M. | SGA % Sales | R&D % Sales | Trading M. | Tax Rate | Net Income | EPS |
| | | | | | | | |
| Ascendis | 52.0% | -0.8% | -23.5% | -30.6% | | | | |
| Lilly | 18.6% | 0.4% | -4.3% | -10.5% | 9.5% | 0.0% | 30.3% | 30.8% |
| Vertex | 9.8% | 0.3% | 1.3% | -19.4% | 50.4% | -25.9% | >100% | >100% |
| Daiichi | 8.6% | 1.5% | 2.3% | -4.3% | 5.2% | 3.7% | 12.1% | 13.4% |
| AbbVie | 7.2% | 0.1% | -3.5% | -5.9% | 4.3% | -1.2% | 12.8% | 12.9% |
| Novo | 7.1% | -0.5% | -1.2% | -1.3% | 0.1% | 0.8% | 6.9% | 7.7% |
| Astra | 6.7% | 0.1% | -3.5% | -0.3% | 3.6% | 0.8% | 11.5% | 11.5% |
| Sanofi | 5.7% | 1.0% | -2.2% | -1.4% | 4.4% | 0.4% | 8.0% | 9.2% |
| Chugai | 5.6% | 1.1% | -2.4% | -1.2% | 2.1% | -1.5% | 8.5% | 8.5% |
| Eisai | 5.6% | -1.2% | -2.4% | -4.8% | 11.0% | 3.0% | 15.2% | 15.2% |
| Novartis | 5.5% | 0.1% | -1.6% | -0.1% | 1.1% | 0.2% | 6.6% | 8.2% |
| JNJ | 5.4% | -0.3% | -1.7% | -4.7% | 3.3% | 2.1% | 7.2% | 8.0% |
| Regeneron | 5.3% | 0.2% | -2.2% | 1.2% | 0.4% | 8.1% | 4.6% | 5.9% |
| Shionogi | 4.9% | -0.9% | -0.2% | -2.1% | -1.1% | 6.4% | 1.6% | 2.3% |
| Amgen | 4.0% | -0.1% | -1.4% | 3.2% | -0.8% | 1.6% | 4.6% | 4.5% |
| Gilead | 3.3% | -0.1% | -2.5% | -11.6% | 10.5% | -6.2% | 17.5% | 17.9% |
| Roche | 2.9% | -0.1% | -0.9% | -1.2% | 1.8% | 2.8% | 5.4% | 5.1% |
| Glaxo | 2.8% | 0.0% | -0.7% | 0.2% | 0.8% | 0.6% | 4.8% | 5.0% |
| Merck | 2.5% | 0.0% | -0.6% | -3.3% | 2.1% | -0.5% | 5.3% | 6.2% |
| Teva | 2.4% | 1.4% | -4.4% | -0.2% | 3.4% | 1.8% | 8.8% | 8.0% |
| Takeda | 1.5% | 0.3% | -0.7% | 0.4% | 16.5% | -8.0% | 6.7% | 4.7% |
| Lundbeck | 1.5% | 0.0% | -1.5% | 3.3% | 4.8% | 7.8% | 1.4% | -2.9% |
| Bayer | 0.8% | 1.1% | -1.5% | -0.8% | 16.5% | | 2.3% | 1.9% |
| Biogen | -0.8% | 0.3% | 0.7% | 0.3% | 0.6% | 2.9% | 0.5% | 0.2% |
| Astellas | -3.5% | -1.0% | -3.1% | 2.1% | 0.7% | -6.2% | 0.2% | 0.4% |
| Pfizer | -4.3% | 0.2% | 0.5% | 2.7% | -1.7% | 1.5% | -6.4% | -6.5% |
| Bristol | -4.9% | 0.3% | 0.9% | -13.3% | 27.1% | -20.4% | 35.1% | 35.2% |
| Neurocrine | | | | | | | | |
| EU Major | 4.5% | 0.4% | -1.9% | -0.6% | 3.0% | 0.5% | 6.9% | 7.0% |
| Other EU | 13.1% | 0.2% | -8.2% | -7.1% | 47.3% | -23.7% | >100% | |
| US Major | 4.8% | 0.3% | -1.9% | -6.7% | 6.0% | -1.5% | 11.3% | 17.5% |
| US Big Biotech | 4.3% | 0.1% | -1.9% | -6.2% | 5.5% | -2.5% | 12.0% | 10.2% |
| Other US | 2.4% | 1.4% | -4.4% | -0.2% | 3.4% | 1.8% | 8.8% | 8.0% |
| Japanese | 3.0% | 0.4% | -0.6% | -1.0% | 6.3% | -0.9% | 7.0% | 7.1% |
